High Definition Medicine Study for Women With Advanced Breast, Lung, or Colon Cancer Starting First-Line Treatment

What this Trial Is About

Researchers are investigating a group of patients with advanced solid tumors who are starting their first line of palliative cancer treatment. The study aims to understand how genetic, phenotypic, environmental, social, and lifestyle factors might relate to how well patients respond to treatment and tolerate it. By collecting detailed personal health information from a large group, the study seeks to identify factors that can help select the best treatments for individual patients. Participants include women with hormone-positive, HER2-negative breast cancer receiving CDK46 inhibitors plus hormone therapy, women with colon cancer, and women with lung cancer starting first-line treatment. The study uses wearable devices to continuously monitor health data and collects various clinical, analytical, and epidemiological information. It includes follow-up for up to 36 months or until death or withdrawal. During the study, participants will wear a Garmin Vivosmart bracelet to track heart rate, oxygen levels, physical activity, and sleep quality. They will also complete questionnaires about quality of life, diet, and mental health. Researchers will analyze how physical activity, tumor stage, and tumor origin relate to treatment response and tolerance. The study monitors adherence to the wearable device and collects data until the participants death or withdrawal, lasting up to 3 years.

High Definition Medicine for Solid Tumors Oncology